Type 1 Diabetes Clinical Trial
Official title:
Obstructive Sleep Apnoea (OSA) in Patients With Type 1 Diabetes (T1D): A Cross-Sectional Study
The primary aim of this study is to assess the relationship between obstructive sleep apnoea
(OSA) and cardiac autonomic neuropathy (CAN) in patients with T1D.
The secondary aims of this study are to assess: (1) the prevalence of OSA in patients with
T1D; (2) the relationship between OSA and metabolic parameters (such as glycaemic control,
blood pressure, lipids and weight) in patients with T1D; (3) the relationship between OSA and
diabetes-related microvascular complications (retinopathy, nephropathy, peripheral
neuropathy) in patients with T1D; and (4) the potential mechanisms for the relationship
between OSA and diabetic-related complications if such a relationship is found.
Obstructive sleep apnoea (OSA) has been reported to be very common in patient with type 2
diabetes (T2D), and this relation is expected as both conditions share obesity as a common
risk factor. Despite that several articles have stated that OSA is an independent risk factor
for abnormal glucose metabolism, hypertension, and cardiovascular diseases.
In contrast, patients with type 1 diabetes (T1D) are leaner and younger than patients with
T2D, so it was expected that OSA might be less common in patients with T1D. However, few
studies have reported the prevalence of OSA in T1D with a range between 8 and 46%. The
relationship between OSA and diabetes-related vascular disease is poorly explored in patients
with T1D. This suggests a mechanism other than obesity may be responsible for OSA in patients
with T1D. Therefore, the investigators hypothesized that (1) OSA is related to CAN rather
than obesity in patients with T1D. (2) OSA is common in patients with T1D. (3) OSA is
associated with worse metabolic profile and microvascular complications in T1D. (4) Oxidative
and nitrosative stress are possible mechanisms relating OSA to T1D complication.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05653518 -
Artificial Pancreas Technology to Reduce Glycemic Variability and Improve Cardiovascular Health in Type 1 Diabetes
|
N/A | |
| Enrolling by invitation |
NCT05515939 -
Evaluating the InPen in Pediatric Type 1 Diabetes
|
||
| Completed |
NCT05109520 -
Evaluation of Glycemic Control and Quality of Life in Adults With Type 1 Diabetes During Continuous Glucose Monitoring When Switching to Insulin Glargine 300 U/mL
|
||
| Recruiting |
NCT04016987 -
Automated Structured Education Based on an App and AI in Chinese Patients With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT04190368 -
Team Clinic: Virtual Expansion of an Innovative Multi-Disciplinary Care Model for Adolescents and Young Adults With Type 1 Diabetes
|
N/A | |
| Recruiting |
NCT05413005 -
Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Type 1 Diabetes Mellitus
|
Early Phase 1 | |
| Active, not recruiting |
NCT04668612 -
Dual-wave Boluses in Children With Type 1 Diabetes Insulin Boluses in Children With Type 1 Diabetes
|
N/A | |
| Recruiting |
NCT05414409 -
The Gut Microbiome in Type 1 Diabetes and Mechanism of Metformin Action
|
Phase 2 | |
| Completed |
NCT02837094 -
Enhanced Epidermal Antigen Specific Immunotherapy Trial -1
|
Phase 1 | |
| Recruiting |
NCT05670366 -
The Integration of Physical Activity Into the Clinical Decision Process of People With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT05418699 -
Real-life Data From Diabetic Patients on Closed-loop Pumps
|
||
| Completed |
NCT04084171 -
Safety of Artificial Pancreas Therapy in Preschoolers, Age 2-6
|
N/A | |
| Recruiting |
NCT06144554 -
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
|
||
| Recruiting |
NCT05281614 -
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
|
Early Phase 1 | |
| Recruiting |
NCT05379686 -
Low-Dose Glucagon and Advanced Hybrid Closed-Loop System for Prevention of Exercise-Induced Hypoglycaemia in People With Type 1 Diabetes
|
N/A | |
| Recruiting |
NCT05153070 -
Ciclosporin Followed by Low-dose IL-2 in Patients With Recently Diagnosed Type 1 Diabetes
|
Phase 2 | |
| Withdrawn |
NCT04259775 -
Guided User-initiated Insulin Dose Enhancements (GUIDE) to Improve Outcomes for Youth With Type 1 Diabetes
|
N/A | |
| Active, not recruiting |
NCT01600924 -
Study on the Assessment of Determinants of Muscle and Bone Strength Abnormalities in Diabetes
|
||
| Completed |
NCT02914886 -
Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)
|
Phase 4 | |
| Completed |
NCT02750527 -
Pediatric Population Screening for Type 1 Diabetes and Familial Hypercholesterolemia in Lower Saxony, Germany
|